PRAX Latest Headlines

Praxis' EMBOLD Study Achieves Early Success—Positive Results for Relutrigine in Rare Epilepsies Spur FDA Meeting

Market Chameleon (Fri, 5-Dec 10:29 AM)

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Protara Therapeutics (TARA)

at www.tipranks.com (Fri, 5-Dec 10:50 AM)

Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Praxis Precision Medicines (PRAX)

at www.tipranks.com (Fri, 5-Dec 9:10 AM)

Analysts Are Bullish on These Healthcare Stocks: Pelthos Therapeutics (PTHS), Praxis Precision Medicines (PRAX)

at www.tipranks.com (Fri, 5-Dec 9:00 AM)

Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

at www.tipranks.com (Fri, 5-Dec 8:45 AM)

Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA)

at www.tipranks.com (Fri, 5-Dec 8:10 AM)

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX)

at www.tipranks.com (Fri, 5-Dec 8:00 AM)

Praxis Precision Medicines: Strong Buy Rating Backed by Regulatory Clarity and Positive Trial Results

at www.tipranks.com (Fri, 5-Dec 7:45 AM)

Praxis Precision Medicines: Buy Rating Affirmed on Regulatory Milestones and Promising Pipeline Developments

at www.tipranks.com (Fri, 5-Dec 7:40 AM)

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

at www.benzinga.com (Fri, 5-Dec 5:03 AM)

3 ‘Strong Buy’ Stocks to Buy Today, 12/4/2025, According to Top Analysts

at www.tipranks.com (Thu, 4-Dec 7:58 AM)

Robustness of Praxis Precision Medicines’ ESSENTIAL3 Program Supports Buy Rating

at www.tipranks.com (Thu, 4-Dec 6:16 AM)

Praxis Precision Medicines (PRAX) Has a New Rating from BTIG

at www.tipranks.com (Wed, 3-Dec 6:53 AM)

PRAX Announces Proposed Public Offering as Investors Eye Strategic Funding Move

Market Chameleon (Fri, 17-Oct 10:34 AM)

Praxis Precision Medicines Reports Significant Phase 3 Success in Essential Tremor—Ulixacaltamide Achieves All Key Endpoints

Market Chameleon (Thu, 16-Oct 9:52 AM)

Ulixacaltamide Shows Robust Efficacy and Tolerability in Phase 3 Essential Tremor Trials—Praxis Targets FDA Submission in 2026

Market Chameleon (Thu, 16-Oct 7:31 AM)